An experts on diabetes

Sygnet BIOTON

OBJECTIVES

Our objective is to become the provider of complete diabetes care solutions and the preferred choice for patients, doctors and the diabetes community.

FOUNDATIONS

Every day we build our global success by strengthening our expertise in diabetes and biotechnology.
We strengthen our operational excellence by being open-minded, target-oriented and working as a team.

BIOTON is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin.

Company
Expert
Process
Analytics
Quality
Biotechnology

Biotechnology

Bioton continuously invests in the development of Polish biotechnology. We are the first and only company in Poland which is able to fully translate its technology into commercial use.

Insulin production

Recombinant human insulin is an efficient and safe therapy for most people suffering from diabetes. We strive to become the provider of complete diabetes care solutions and the preferred choice for patients, doctors and the diabetes community.

European quality

Safety and the highest quality of products, and Patients’ needs are key in our activities, thus we entrust them to a competent and highly specialized team of experts.

Thanks to innovative technologies, all our products are manufactured in conditions that meet the international Good Manufacturing Practice standard, which is confirmed by numerous GMP certificates.

Environment protection

Responsibility for the natural environment in one of BIOTON’s priorities. All our activities are aimed at minimizing the amount of emitted pollutants and substances that may have a negative influence on the environment. We continuously promote green initiatives among our employees and support environmental education.

The story and development of Bioton

Modern manufacturing site
Over
550
employees
Total
investment
value of PLN
760
million
Investing
in innovation
Since 2010 BIOTON
has allocated over PLN on for R&D
126
million
Works on analogs entail
a further PLN invested in research
and licensing processes by 2023
400
million

Bioton worldwide

For over 20 years, we have been providing day-to-day support to patients suffering from diabetes all over the world. Today, our insulins are available in more than 20 countries in Europe, South America, Asia and Africa. Responding to our partners’ varied needs, we supply finished forms of insulin and the active pharmaceutical ingredient (API), at the same time offering a technology transfer. We continuously work on improving the availability of our insulins in new countries by developing technology, education and providing scientific support to local communities. International sales and licensing of Bioton insulins Current situation In licensing.

chorzy na cukrzycę na świecie

International sale and registration of Bioton insuling

  • Registration
  • On-Going registration